Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings or view top-rated stocks.

Galmed Pharmaceuticals' stock was trading at $7.50 at the start of the year. Since then, GLMD stock has decreased by 42.0% and is now trading at $4.35.
View the best growth stocks for 2023 here.

Galmed Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 19,800 shares, an increase of 1,700.0% from the April 30th total of 1,100 shares. Based on an average daily volume of 23,100 shares, the short-interest ratio is currently 0.9 days. Currently, 1.4% of the company's shares are sold short.
View Galmed Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our GLMD earnings forecast.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings data on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41.

Galmed Pharmaceuticals's stock reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Galmed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.35%).

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLMD stock can currently be purchased for approximately $4.35.

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $7.31 million. The biopharmaceutical company earns $-17,870,000.00 in net income (profit) each year or ($7.9866) on an earnings per share basis.

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.